Loading…
Employees: 517
Size TTY Biopharm (4105.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $596M, the 394th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$79.20 on 6 Nov 2026.
Performance Over six months the shares gained 6.7%, against -22.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 4.5% over the last twelve months (peer median -1.7%); the operating margin is 32.9% (peer median 4.3%).
Valuation It trades at 10.9× forward earnings against a peer median of 12.6× (4th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -20 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 19.0 points above its cost of capital (5.0% WACC).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$6.81B | NT$6.45B | NT$5.90B | NT$5.50B | NT$5.06B |
| Revenue growth | — | +9% | +7% | +9% | — |
| Gross profit | NT$4.06B | NT$3.67B | NT$3.36B | NT$3.22B | NT$2.96B |
| EBITDA | n/a | NT$1.90B | NT$1.60B | NT$1.57B | NT$1.41B |
| Net income | NT$1.73B | NT$1.56B | NT$1.45B | NT$1.13B | NT$1.09B |
| Free cash flow | n/a | NT$1.71B | NT$1.26B | NT$1.07B | NT$1.19B |
| Capital expenditure | n/a | NT$173M | NT$153M | NT$160M | NT$181M |
| Total debt | n/a | NT$1.23B | NT$1.76B | NT$1.92B | NT$1.87B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4105.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.1% | -7.2% | 6th highest of 21 |
| 6-month return | +6.7% | -22.1% | 4th highest of 21 |
| Distance from 52-week high | -9.0% | -36.2% | 2nd highest of 21 |
| Revenue growth (TTM) | +4.5% | -1.7% | 8th highest of 18 |
| Operating margin | 32.9% | 4.3% | highest of 18 |
| Forward P/E | 10.9× | 12.6× | 4th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -11.1% | 5.3% | 2nd least demanding of 9 |
| Growth delivered (Del g) | +8.8% | +5.8% | 4th highest of 9 |
| Hurdle (Req g minus delivered) | -19.9 pp | -3.0 pp | least demanding of 9 |
| ROIC minus cost of capital | +19.0 pp | -2.1 pp | highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 10.9× | -11.1% | +8.8% |
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 23.6× | 27.9% | +15.8% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 9.7× | -3.2% | +4.1% |
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | n/a | n/a | n/a |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | n/a | n/a | n/a |
| Jinhe Biotechnology 002688.SZ | China | $587M | -22% | +9% | 5% | 9.5× | 14.8% | +9.7% |
| Jinling Pharmaceutical 000919.SZ | China | $586M | -14% | -8% | 1% | n/a | 5.0% | +5.0% |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 12.6× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 10.9× | -14.3% | +2.8% |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 30.4× | 25.4% | +31.4% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | n/a | 5.5% | -1.1% |
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 34.2× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | n/a | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | n/a | n/a | n/a |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 7.1× | -4.9% | +6.5% |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | n/a | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 75.5× | n/a | n/a |